Articles About Medtech

The Answer to Big Pharma’s Biggest Problem Could Double Your Money in just Three Years

0 | By Michael A. Robinson

You could forgive drug and biotech executives for having a bad case of target fixation.

After all, they do work in a field that is filled with time-consuming and expensive headaches.

Consider that the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.

The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That’s a one-in-ten shot.

With such daunting data, it’s no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.

And with that goal in mind, I’ve uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector’s success.

It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months

It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months

My Top Three Recommendations for New Investors

0 | By Michael A. Robinson

My “dad vibe” must be working overtime these days.

And that’s got me thinking maybe my “chance” conversations with a number of young adults lately is a sign of the times.

Let me explain.

As I’ve been going about my routines in the past, I’ve run into a lot of young people who want to get started in investing, but have no clue how to do so.

I’m talking about folks my daughters’ age who are earning some income and want to invest, but just don’t know where to start.

For instance, once, while skiing at the Kirkwood Mountain Resort near Lake Tahoe, I chatted with three young adults who jumped at the chance to get my advice about investing.

I guess that’s where the dad vibe comes into play…. I told them about a surefire way to make the market work for them as though I were talking to my own daughters.

And it just so happens that this investment advice is good for newcomers and old, particularly investors who’ve been reluctant to jump in when market conditions are so volatile.

That’s why today, I’m going to show you not just the one “starter” investment vehicle I suggest for young adults that can set you on the right track…

But I’m going to recommend three other tech-centric ways to jump start your portfolio right now…

Check it out

The “Printing” Tech Tackling Heart Disease’s $400 Billion in Annual Costs

0 | By Michael A. Robinson

There’s a new cutting-edge tech breakthrough that could save the lives of six million Americans in a decade.

Yes, it is potentially a very powerful weapon in the fight against heart disease, which the U.S. Centers for Disease Control and Prevention says causes one in four deaths each year.

Ironically, the technology is in a sector deeply out of favor with Wall Street.

But that’s just fine with us. At Strategic Tech Investor, we know the huge profit potential in bucking the Street’s herd mentality.

And you couldn’t pick a more exciting field than 3D-printed human organs.

Here’s the thing. Scientists in Israel printed a tiny heart in April, complete with blood vessels, using a patient’s cells.

Even better, they pulled off this amazing achievement in just three hours.

That’s why today, I’m going to show you what I believe is the best market-crushing play on the future of 3D printing tech used to save lives…

Check it out

This Pick Is Just What the Software Engineer Ordered

1 | By Michael A. Robinson

I’m not average.

For one, I’m a bit taller than the average guy. My hair went silver earlier than I expected. And I’m fortunate that it’s easier for me to keep trim than a lot of people I know.

On the downside, I’ve got various allergies and genetic maladies that most folks don’t.

My environment isn’t average either. Here in Silicon Valley and the San Francisco Bay Area, I spend my days in some of the most polluted cities in the United States. Of course, in other ways, this region rates much higher than most of America.

Then there are my habits. For example, I eat well, but don’t get to the gym enough.

I bet you’re the same way – but different.

No one is average.

And that’s why it often seems like maintaining a healthy diet, getting plenty of exercise, and regular checkups just aren’t enough to keep us healthy. If it were, no one would gain too much weight, go bald at 30, or get cancer.

By our very nature, each of us is so unique that this one-size-fits-all approach just isn’t enough.

That’s what opened the door for an emerging field known as precision medicine. The idea here is to set up disease prevention and treatment measures for each and every individual, accounting for your genes, environment, and lifestyle… for my genes, environment, and lifestyle.

Think of it as a partnership – a “convergence” – among traditional medicine, molecular biology, data analysis, and cloud computing.

Doctors and other medical diagnosticians collect our info, and then feed it to the cloud. There software and data scientists can crunch through all that data – and then use what they turn up to prescribe precise disease treatments and preventative measures for each individual.

Mordor Intelligence has run the numbers – and says precision medicine will be worth $59.2 billion by 2021

And I’ve spotted a hidden way to play this hot new field with a stock with which you’ll soon be quadrupling the market’s return

The Opioid Crisis Is Now a National “Public Health Emergency” – and This One Company Could Help End It

2 | By Michael A. Robinson

Thanks to legal recreational use of marijuana about to launch in California and nationwide up in Canada, sometimes it’s easy to forget where we got started here.

Legal marijuana first came to my attention because of the “War on Pain.”

Let me explain…

In a study a year or so ago, the National Institutes of Health (NIH) found that about 11% of Americans suffered from debilitating pain. Other sources say the number of this country’s pain sufferers may run as high as 50 million.

But I don’t need statistics to know that millions of Americans suffer from serious pain problems.

I do so myself – and so do many of my friends and family members.

And that has turned the market for pain medication into a huge business. According to market researcher VisionGain, the worldwide business for pain drugs is worth about $68 billion right now.

Other studies say it’s even bigger.

Equally huge is the nation’s opioid crisis.

President Donald Trump has declared the opioid crisis a “public health emergency,” and a White House commission has released its final report on the epidemic, calling for more drug courts, greater training for doctors, and penalties for insurers who do not cover addiction treatment.

The number of opioid-related deaths rose 75%, from roughly 20,000 in 2010 to 35,000 in 2015. In other words, opioid-based drugs kill more than 100 Americans every day.

This surge in the number of pain sufferers – coupled with the snapback against the prescription of opioid drugs – has opened the door to a wholly new approach to pain treatment.

I’m talking about medical marijuana and all its derivatives.

And there’s one company, in particular, that you should be watching…

This Stock Market “Deal” Is Almost too Good to Be True

4 | By Michael A. Robinson

In a perfect world, we’d all have access to the same information, and stocks would price themselves quickly and accurately, and there’d be no “mystery” or uncertainty in taking a position.

It’s a pretty thought.


Only there is one catch – there wouldn’t be any massive opportunities like the one I’m going to show you, either.

You see, as a thrifty man, I’m always hunting for a good deal.

But the best, most satisfying, ones are always those that effortlessly fall into your lap.

And that’s exactly the kind of play that we’re going to look at.

What I’m going to show you is the next best thing to getting something for nothing.

It’s not unlike what used to happen in brick-and-mortar stores back in the day, before barcodes and RFID tags, when a high school kid would go around with a sticker gun, sticking prices on items, and make a mistake.

It might not have been so great for the employee, but it was always a sweet feeling for the consumer to get an unexpected deal.

Well, the exact same thing is happening right now in one of the best pharma companies on the market…

And it’s a “sweet deal” investors won’t want to miss out on…

Here’s what else I’m following

A Trump Presidency Means Good Things for This Pharma Stock

5 | By Michael A. Robinson

Like many issues, Donald Trump has been all over the map on the legal marijuana question.

Way back in 1990, the president-elect said the United States needed to legalize all drugs and use the tax revenue to educate Americans about the dangers of drugs. (He may have been joking.)

More recently, he’s been hesitant on legal recreational marijuana but bullish on the medical kind.

“In terms of marijuana and legalization, I think that should be a state issue, state-by-state,” Trump recently told reporters. “Marijuana is such a big thing. I think medical should happen – right? Don’t we agree? I think so. And then I really believe we should leave it up to the states.”

weedWhatever Trump’s opinion, the overwhelming “Yes” vote on Nov. 8 just unleashed a tsunami of cash.

That tsunami is heading in the direction of marijuana companies – and in the direction of those companies’ investors.

Already, one of those medical “pot stocks” is starting to pull ahead of the pack.

That’s because it’s clear that Trump’s position on medical marijuana will boost the fortunes of companies that are working on marijuana-derived pharmaceuticals. Companies just like this one.

And you could boost your own fortune with it.

Here’s how…

To continue reading click here.

Introducing “Wearapeutics” – and the Best Way to Get the Most Profits Out of It

0 | By Michael A. Robinson

The Internet of Everything, a vast network of devices like phones, watches, clothing and even toothbrushes – all communicating, all collecting and returning data – has been one of the biggest tech stories of the past five years.

But I’m here to tell you that it’s about to get even bigger, even more profitable, by an order of magnitude. That’s because the Internet of Everything is about to crack open the healthcare market, with small networked wearable medical, prosthetic, and therapeutic devices set to explode onto the market.

I’m talking about wearable therapeutics – or “wearapeutics.” It’s going to be a healthcare game changer.

Today, I’m showing you just how big the wearapeutics market is going to get – and the one investment you need to hold long term to get the most profits out of this exciting development.

Take a look…

As Gene Therapies Disrupt Big Pharma, Here’s How to Get Your Piece of the Action

4 | By Michael A. Robinson

A doctor injects a “corrective” gene into a virus. Then he uses that virus to introduce the new gene and modified DNA into a patient’s diseased cells. If the treatment is successful, the cells’ gene-reading machinery will build RNA messengers and protein molecules – i.e., disease fighters.

It’s a process that could be a cure for hundreds of genetic-related diseases.

That’s gene therapy in action.

When biotech researchers get gene therapy to work dependably, it will be a boon for humanity – and for investors.

For decades, Big Pharma has run on the same basic plan – use chemicals to create disease-fighting drugs. However, many of the drugs they end up creating carry severe side effects or are highly addictive.

But now, after a quarter century of failed experiments and numerous setbacks, gene therapy finally has the potential to make patients well again without addictive or harmful drugs.

Researchers worldwide report successful gene-therapy trials – and new and innovative uses for the technology – seemingly every week. The first federally approved gene therapy, the severe pancreatitis treatment Glybera, hit the market in late 2014 as. And I think the next half decade will bring dozens more gene-therapy products along those same lines.

Now, finding a way to invest in this newly disruptive biotechnology is tough. Most of the companies working on gene therapies are privately held or very risky, illiquid clinical-stage biotech companies that I just can’t recommend to beginning investors.

However, I have located a great backend way to play this breakthrough field. Its stock has soared 25% in just the past five months or so – and it shows no sign of slowing down. Plus, it pays a healthy 2% dividend.

Let me show it to you…

To continue reading click here.